Protecting and Commercializing Proprietary Life Sciences Technologies Beyond Patents
Because patents are considered the strongest form of IP protection, life sciences companies often rely on patent laws to protect the valuable IP derived from enormous investments in new discoveries. But what if your company cannot obtain patent protection for a valuable technology or discovery? How can you protect your asset while a patent application is pending — or before it is filed? What if the patent your company was ultimately able to obtain does not provide full protection? How can you commercialize a self-replicating biological product absent patent protection?
Please join us for a Foley Executive Briefing Series program exploring how you can draw upon legal concepts and approaches beyond patent laws in order to develop commercialization strategies involving biological products, including cell lines, transgenic animals, and plants. These approaches include:
- The laws of bailment, personal property leases, and the Uniform Commercial Code (UCC) for commercialization strategies of non-patented biological products
- Material transfer agreements
- License agreements in a post-Quanta world
- Handelsmerken
Join Foley Business Law Partner Sven Riethmueller and IP Partner James F. Ewing for this interactive panel session, which also will present a case study outlining the successful commercialization of a non-patented biological product.
Protecting and Commercializing Proprietary Life Sciences Technologies Beyond Patents is part of the Foley Executive Briefing Series. Learn more about programs in the series at Foley.com/FEBS.
